Pfizer Inc. (PFE)

38.50
0.23 0.60
NYSE
Prev Close 38.27
Open 38.30
Day Low/High 38.16 / 38.62
52 Wk Low/High 27.88 / 40.97
Volume 13.64M
Exchange NYSE
Shares Outstanding 5554.83B
Market Cap 213.58B
P/E Ratio 13.73
Div & Yield N.A. (N.A)
Cornerstone Stocks:10 Companies in High-Demand Markets

Cornerstone Stocks:10 Companies in High-Demand Markets

These high-quality companies have strong balance sheets and operate in high-demand markets poised to do well through any economic crisis.

Sell Signals, 'Operation Warp Speed,' Trading Notes

Sell Signals, 'Operation Warp Speed,' Trading Notes

Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.

Jim Cramer: Let the Froth Wash Out

Jim Cramer: Let the Froth Wash Out

Let's look at the stocks that will get crushed and that you can't touch right now.

Want to Know Why I'm Not Selling Moderna?

Want to Know Why I'm Not Selling Moderna?

I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.

This Chart Pattern Hints at a Bullish Future

This Chart Pattern Hints at a Bullish Future

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.

Covering All Bases With Pfizer as It Aggressively Pursues a Covid-19 Vaccine

Covering All Bases With Pfizer as It Aggressively Pursues a Covid-19 Vaccine

PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.

Earnings in Full Swing, Workplace Evolution, Fed Day

Earnings in Full Swing, Workplace Evolution, Fed Day

There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.

Can a Covid-19 Vaccine Power Shares of Pfizer Higher?

Can a Covid-19 Vaccine Power Shares of Pfizer Higher?

PFE's charts are constructive and traders could go long at current levels.

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

Small-Caps Roar, Bets Against the Market, Trading Nvidia

Small-Caps Roar, Bets Against the Market, Trading Nvidia

Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.

Jim Cramer: How to Stay Safe, Until Quick Testing for Covid-19 Is Available

Jim Cramer: How to Stay Safe, Until Quick Testing for Covid-19 Is Available

Welcome to the new era. Social distancing is not without risks, but it is as good as it gets.

I'm Dusting Off My Old Playbook for Bonds Right Now

I'm Dusting Off My Old Playbook for Bonds Right Now

After a strong day for fixed-income markets, let's learn from 2008 how to play this volatility.

The Magic Mice of Regeneron

The Magic Mice of Regeneron

I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.

Thank the Fed, Cessation of Economic Activity, Rescuing Airlines, 3 Key Stocks

Thank the Fed, Cessation of Economic Activity, Rescuing Airlines, 3 Key Stocks

When the central bank is on top of their game as they have been of late, credit must go where credit is due.

No Bottom Yet for Pfizer's Charts but We Have Price Targets to Watch

No Bottom Yet for Pfizer's Charts but We Have Price Targets to Watch

The daily trading volume has increased over the past two months telling us that PFE is not falling of its own weight but rather investors are voting with their feet.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Pfizer Has an Attractive Dividend Yield, but What Do Its Charts Reveal?

Pfizer Has an Attractive Dividend Yield, but What Do Its Charts Reveal?

Here's how we would play shares of the pharmaceutical giant now.

Jim Cramer: Are These 10 High-Yielding Stocks on Your Radar?

Jim Cramer: Are These 10 High-Yielding Stocks on Your Radar?

These Dow stocks all yield above 3.3% right now, but are they worth the risk?

Shaky Markets, Economic Effects of Coronavirus, FOMC Meets, 3 Trading Thoughts

Shaky Markets, Economic Effects of Coronavirus, FOMC Meets, 3 Trading Thoughts

This coronavirus remains a China-centric problem? People are not yet dying in other countries. Do we have to worry here? That's the wrong question.

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

3 Sectors to Watch, First Quarter Volatility, 10 Dow Dogs: Market Recon

3 Sectors to Watch, First Quarter Volatility, 10 Dow Dogs: Market Recon

Also: People's Bank of China, the Fed, U.S./China trade deal, Brexit, USMCA.

Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets

Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets

The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Pfizer Upgraded to Hold at DZ Bank

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Pfizer Downgraded at Morgan Stanley

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.